TR200002615T2 - Aspartil proteaz inhibitörleri önilaçları olarak sülfonamit türevleri. - Google Patents

Aspartil proteaz inhibitörleri önilaçları olarak sülfonamit türevleri.

Info

Publication number
TR200002615T2
TR200002615T2 TR2000/02615T TR200002615T TR200002615T2 TR 200002615 T2 TR200002615 T2 TR 200002615T2 TR 2000/02615 T TR2000/02615 T TR 2000/02615T TR 200002615 T TR200002615 T TR 200002615T TR 200002615 T2 TR200002615 T2 TR 200002615T2
Authority
TR
Turkey
Prior art keywords
prodrugs
protease inhibitors
relates
aspartyl protease
sulfonamide derivatives
Prior art date
Application number
TR2000/02615T
Other languages
English (en)
Turkish (tr)
Inventor
D. Tung Roger
R. Hale Michael
T. Baker Christopher
Steven Furfine Eric
Kaldor Istvan
Mieczyslaw Kazmierski Wieslaw
Spaltenstein Andrew
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200002615(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of TR200002615T2 publication Critical patent/TR200002615T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
TR2000/02615T 1997-12-24 1998-03-09 Aspartil proteaz inhibitörleri önilaçları olarak sülfonamit türevleri. TR200002615T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
TR200002615T2 true TR200002615T2 (tr) 2001-01-22

Family

ID=25544691

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02615T TR200002615T2 (tr) 1997-12-24 1998-03-09 Aspartil proteaz inhibitörleri önilaçları olarak sülfonamit türevleri.

Country Status (42)

Country Link
US (5) US6436989B1 (OSRAM)
EP (2) EP1944300A3 (OSRAM)
JP (3) JP3736964B2 (OSRAM)
KR (1) KR100520737B1 (OSRAM)
CN (2) CN100503589C (OSRAM)
AP (1) AP1172A (OSRAM)
AR (1) AR017965A1 (OSRAM)
AT (1) ATE382042T1 (OSRAM)
AU (1) AU755087B2 (OSRAM)
BG (1) BG64869B1 (OSRAM)
BR (1) BR9814480A (OSRAM)
CA (1) CA2231700C (OSRAM)
CO (1) CO4990992A1 (OSRAM)
CZ (1) CZ301653B6 (OSRAM)
DE (2) DE122008000021I2 (OSRAM)
DK (1) DK0933372T3 (OSRAM)
EA (1) EA003509B1 (OSRAM)
EE (1) EE04466B1 (OSRAM)
ES (1) ES2299193T3 (OSRAM)
FR (1) FR08C0015I2 (OSRAM)
HU (2) HU229596B1 (OSRAM)
ID (1) ID24962A (OSRAM)
IL (2) IL136941A0 (OSRAM)
IS (1) IS2817B (OSRAM)
LU (1) LU91426I2 (OSRAM)
ME (1) MEP82008A (OSRAM)
MY (1) MY131525A (OSRAM)
NL (1) NL300339I2 (OSRAM)
NO (2) NO326265B1 (OSRAM)
NZ (1) NZ505776A (OSRAM)
OA (1) OA11468A (OSRAM)
PE (1) PE20000048A1 (OSRAM)
PL (1) PL202845B1 (OSRAM)
PT (1) PT933372E (OSRAM)
RS (1) RS52483B (OSRAM)
SI (1) SI0933372T1 (OSRAM)
SK (1) SK287123B6 (OSRAM)
TR (1) TR200002615T2 (OSRAM)
TW (1) TW486474B (OSRAM)
UA (1) UA72733C2 (OSRAM)
WO (1) WO1999033815A1 (OSRAM)
ZA (1) ZA9811830B (OSRAM)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
HRP20030735B1 (en) 2001-02-14 2012-02-29 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
JP4417010B2 (ja) 2001-04-09 2010-02-17 テイボテク・フアーマシユーチカルズ・リミテツド 広範囲２−（置換−アミノ）−ベンズオキサゾールスルホンアミドｈｉｖプロテアーゼ阻害剤
AR035970A1 (es) 2001-05-11 2004-07-28 Tibotec Pharm Ltd 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ATE446298T1 (de) 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
EP1463502B1 (en) 2001-12-21 2011-07-13 Tibotec Pharmaceuticals Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
CN1656109A (zh) * 2002-04-26 2005-08-17 吉里德科学公司 非核苷逆转录酶抑制剂
US7462636B2 (en) 2002-05-17 2008-12-09 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors
EA010486B1 (ru) 2002-08-14 2008-10-30 Тиботек Фармасьютикалз Лтд. Замещенные оксиндолсульфонамидные ингибиторы вич-протеазы широкого спектра действия
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7417055B2 (en) 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
US20050137174A1 (en) * 2003-07-09 2005-06-23 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
EP2295404A3 (en) 2003-07-09 2011-05-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
WO2005058311A1 (en) * 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1697384B1 (en) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
EP2336138A3 (en) 2004-07-06 2011-11-16 Abbott Laboratories Prodrugs of HIV protease inhibitors
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
EP2165709B1 (en) * 2004-08-02 2016-03-16 Ambrilia Biopharma Inc. Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent
RU2379312C2 (ru) * 2004-08-02 2010-01-20 Амбрилиа Байофарма Инк. Соединения на основе лизина, фармацевтическая композиция, содержащая эти соединения, применение указанных соединений для лечения или профилактики вич инфекции
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
WO2006024489A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
CN101098698A (zh) 2004-12-01 2008-01-02 德福根有限公司 与离子通道尤其是Kv家族离子通道相互作用的5-羧酰胺基取代的噻唑衍生物
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
EP1969939A3 (en) 2004-12-17 2008-12-03 Devgen NV Nematicidal compositions
BRPI0606318B8 (pt) * 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
EP1855672A4 (en) * 2005-03-11 2011-11-30 Glaxosmithkline Llc HIV PROTEASE INHIBITORS
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
EP1877091B1 (en) * 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
EP1940856B1 (en) 2005-10-21 2014-10-08 Universiteit Antwerpen Novel urokinase inhibitors
AR058238A1 (es) 2005-11-28 2008-01-23 Tibotec Pharm Ltd Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
AR057182A1 (es) 2005-11-28 2007-11-21 Tibotec Pharm Ltd Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
CN102898519B (zh) 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
ES2452718T3 (es) * 2005-11-30 2014-04-02 Taimed Biologics, Inc. Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
BRPI0620715A2 (pt) 2005-12-27 2011-11-22 Otsuka Pharma Co Ltd composto da benzoazepina solúvel em água e a sua composição farmacêutica
ES2569428T3 (es) 2006-07-13 2016-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina como MTKI
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
EP2064177B1 (en) 2006-09-21 2017-04-05 TaiMed Biologics, Inc. Protease inhibitors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
AU2008226823B2 (en) 2007-03-12 2014-03-13 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US8318929B2 (en) 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
NZ590075A (en) 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
US9085592B2 (en) 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
EP2501431B1 (en) 2009-11-19 2020-01-08 Wellinq Medical B.V. Narrow profile composition-releasing expandable medical balloon catheter
WO2011085130A1 (en) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
DK3494972T3 (da) 2010-01-27 2024-01-29 Viiv Healthcare Co Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
WO2011158259A1 (en) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
EP2614055A2 (en) 2010-09-10 2013-07-17 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) * 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
CN120555426A (zh) 2011-06-21 2025-08-29 阿尔尼拉姆医药品有限公司 血管生成素样3（ANGPTL3）iRNA组合物及其使用方法
WO2012178033A2 (en) 2011-06-23 2012-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2013009844A2 (en) * 2011-07-11 2013-01-17 Purdue Research Foundation C-3 substituted bicyclooctane based hiv protease inhibitors
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (en) 2012-06-20 2015-04-29 Sylphar Nv Strip for the delivery of oral care compositions
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
EP3336187A1 (en) 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9 irna compositions and methods of use thereof
MX366660B (es) 2013-03-14 2019-07-18 Alnylam Pharmaceuticals Inc Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
MY181888A (en) 2013-05-22 2021-01-12 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
PE20210921A1 (es) 2013-05-22 2021-05-19 Alnylam Pharmaceuticals Inc Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
IL282401B (en) 2013-12-12 2022-08-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
AU2015217301A1 (en) 2014-02-11 2016-08-25 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
EA201692370A1 (ru) 2014-05-22 2017-03-31 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212196A4 (en) 2014-10-29 2018-07-11 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
HK1244843A1 (zh) 2014-11-17 2018-08-17 Alnylam Pharmaceuticals, Inc. 载脂蛋白c3(apoc3)irna组合物及其使用方法
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
MX392757B (es) 2015-04-13 2025-03-24 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico de interferencia (arni) de angiopoyetina-tipo 3 (angptl3) y método de uso de las mismas.
PT3288637T (pt) 2015-04-28 2022-10-11 Newsouth Innovations Pty Ltd Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia
TWI727948B (zh) 2015-05-06 2021-05-21 美商阿尼拉製藥公司 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2017100236A1 (en) 2015-12-07 2017-06-15 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
WO2018112320A1 (en) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
JP7158466B2 (ja) 2017-05-11 2022-10-21 リマインド エヌ．ヴェー． てんかん、神経変性疾患、及び他のｃｎｓ疾患を治療するための化合物
EP3634407A1 (en) 2017-05-11 2020-04-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
US20200163987A1 (en) 2017-07-10 2020-05-28 Genzyme Corporation Methods and compositions for treating a bleeding event in a subject having hemophilia
CN111107850A (zh) 2017-07-21 2020-05-05 Viiv保健公司 用于治疗hib感染和aids的方案
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2020036862A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
SG11202107669WA (en) 2019-01-16 2021-08-30 Genzyme Corp Serpinc1 irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
JP2023514443A (ja) 2020-02-24 2023-04-05 カトリーケ、ユニベルシテート、ルーベン ピロロピリジンおよびイミダゾピリジン抗ウイルス化合物
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CA3203612A1 (en) 2020-12-22 2022-06-30 Luxembourg Institute Of Health (Lih) Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
WO2022184898A1 (en) 2021-03-04 2022-09-09 Universiteit Antwerpen Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
MX2023014255A (es) 2021-05-31 2024-01-18 Telix Pharmaceuticals Innovations Pty Ltd Antigeno de membrana especifico de la prostata mejorado dirigido a radiofarmaceuticos y sus usos.
EP4387629A1 (en) 2021-08-18 2024-06-26 Katholieke Universiteit Leuven KU Leuven Research & Development 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
EP4405357A1 (en) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections
WO2024062043A1 (en) 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
WO2024175804A1 (en) 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators
WO2025104221A1 (en) 2023-11-15 2025-05-22 Université Libre de Bruxelles Uses of protein tyrosine phosphatase receptor kappa inhibitors
WO2025157901A1 (en) 2024-01-26 2025-07-31 Aneurotech Bv Piperidine carboxamide fatty acid prodrugs

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
NL8800100A (nl) 1987-01-21 1988-08-16 Sandoz Ag Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
JPH07502970A (ja) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー １，４―ジアミノ―２，３―ジヒドロキシブタン類
TW225540B (OSRAM) 1990-06-28 1994-06-21 Shionogi & Co
DE69129235T2 (de) 1990-11-19 1998-11-12 Monsanto Co Retrovirale proteaseinhibitoren
EP0731088B1 (en) 1990-11-19 2000-10-04 Monsanto Company Retroviral protease inhibitors
ATE155779T1 (de) 1990-11-19 1997-08-15 Monsanto Co Retrovirale protease-inhibitoren
JPH06503092A (ja) 1990-11-19 1994-04-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
DK0541168T3 (da) 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
DE69304051T2 (de) 1992-05-20 1997-01-23 Monsanto Co Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
ATE199545T1 (de) 1992-05-21 2001-03-15 Monsanto Co Inhibitoren retroviraler proteasen
EP0656888B1 (en) 1992-08-25 1998-01-07 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ATE154800T1 (de) 1992-08-25 1997-07-15 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
AU680635C (en) 1992-08-25 2007-05-17 G.D. Searle Llc Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JPH07501085A (ja) * 1992-09-03 1995-02-02 ベーリンガー　インゲルハイム　コマンディトゲゼルシャフト 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
DK0810208T3 (da) 1992-10-30 2002-03-18 Monsanto Co N-substituerede hydroxyethylamino sulfaminsyrederivater til anvendelse som inhibitorer af retrovirale proteaser
EP0666843B1 (en) 1992-10-30 1999-08-18 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
MY128102A (en) 1993-02-17 2007-01-31 Chugai Pharmaceutical Co Ltd Indolin-2-one-derivatives
AU7669794A (en) 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
IL136940A0 (en) * 1997-12-24 2001-06-14 Vertex Pharma Sulphonamide derivatives and pharmaceutical compositions containing the same
US6319946B1 (en) * 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease

Also Published As

Publication number Publication date
LU91426I9 (OSRAM) 2018-12-28
EE200000385A (et) 2001-12-17
AR017965A1 (es) 2001-10-24
IS2817B (is) 2012-11-15
NL300339I2 (nl) 2009-11-02
ZA9811830B (en) 2000-06-23
US6559137B1 (en) 2003-05-06
KR100520737B1 (ko) 2005-10-12
JP4282639B2 (ja) 2009-06-24
SK9662000A3 (en) 2001-02-12
ATE382042T1 (de) 2008-01-15
RS52483B (sr) 2013-02-28
DK0933372T3 (da) 2008-04-28
ES2299193T3 (es) 2008-05-16
EP1944300A3 (en) 2008-11-05
US7592368B2 (en) 2009-09-22
DE69838903T2 (de) 2008-09-18
LU91426I2 (fr) 2008-06-02
CN101565412A (zh) 2009-10-28
DE122008000021I1 (de) 2008-08-14
YU39800A (sh) 2004-03-12
EA003509B1 (ru) 2003-06-26
SK287123B6 (sk) 2009-12-07
IS5546A (is) 2000-06-22
EP0933372B1 (en) 2007-12-26
NZ505776A (en) 2003-06-30
US6838474B2 (en) 2005-01-04
AP2000001850A0 (en) 2000-06-30
CA2231700A1 (en) 1999-06-24
JP2009102400A (ja) 2009-05-14
BR9814480A (pt) 2001-09-25
NL300339I1 (nl) 2008-06-02
IL136941A0 (en) 2001-06-14
OA11468A (en) 2004-05-05
NO2009008I2 (OSRAM) 2010-09-27
HU229596B1 (en) 2014-02-28
HK1021737A1 (en) 2000-06-30
NO2009008I1 (OSRAM) 2009-05-04
UA72733C2 (en) 2005-04-15
MEP82008A (en) 2011-12-20
CZ20002363A3 (cs) 2000-11-15
NO20003304D0 (no) 2000-06-23
IL136941A (en) 2006-06-11
JP2005350478A (ja) 2005-12-22
ID24962A (id) 2000-08-31
HUP0101831A3 (en) 2002-08-28
ME00561B (me) 2011-10-10
NO326265B1 (no) 2008-10-27
PL202845B1 (pl) 2009-07-31
JPH11209337A (ja) 1999-08-03
CN1284071A (zh) 2001-02-14
US20050148548A1 (en) 2005-07-07
BG104631A (en) 2001-02-28
AU6546698A (en) 1999-07-19
EP1944300A2 (en) 2008-07-16
PE20000048A1 (es) 2000-02-08
BG64869B1 (bg) 2006-07-31
US20030207871A1 (en) 2003-11-06
PL342113A1 (en) 2001-05-21
HUS1400042I1 (hu) 2017-06-28
SI0933372T1 (sl) 2008-06-30
CZ301653B6 (cs) 2010-05-12
FR08C0015I1 (OSRAM) 2008-05-30
DE122008000021I2 (de) 2010-02-04
US6436989B1 (en) 2002-08-20
EE04466B1 (et) 2005-04-15
EP0933372A1 (en) 1999-08-04
WO1999033815A1 (en) 1999-07-08
JP3736964B2 (ja) 2006-01-18
CO4990992A1 (es) 2000-12-26
FR08C0015I2 (fr) 2009-10-30
EA200000703A1 (ru) 2000-12-25
KR20010033600A (ko) 2001-04-25
TW486474B (en) 2002-05-11
CA2231700C (en) 2005-08-09
DE69838903D1 (de) 2008-02-07
AP1172A (en) 2003-06-30
NO20003304L (no) 2000-08-21
HUP0101831A2 (hu) 2002-04-29
MY131525A (en) 2007-08-30
CN100503589C (zh) 2009-06-24
AU755087B2 (en) 2002-12-05
PT933372E (pt) 2008-03-31
US20100124543A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
TR200002615T2 (tr) Aspartil proteaz inhibitörleri önilaçları olarak sülfonamit türevleri.
AP2000001856A0 (en) Prodrugs of aspartyl protease inhibitors.
WO1999033792A3 (en) Prodrugs os aspartyl protease inhibitors
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
SE0001899D0 (sv) New compounds
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
ES2055860T3 (es) Derivados 2-aminopirimidinona.
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
TR200400234T4 (tr) ''Stabil, nazal, oral veya sublingual uygulanabilen, desmopressin ihtiva eden farmasötik preparasyon''
PL346764A1 (en) New oral formulation for 5-ht4
DE50012571D1 (de) Biotin enthaltende galenische formulierung
BG106155A (en) Novel derivatives and analogues of galanthamin
HUP0203716A2 (hu) Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények
ATE253359T1 (de) Antithrombotische mittel
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.